Pharmacological treatments for tinnitus: New and old

Drugs of the Future

Volumn 34, Issue 5, 2009, Pages 381-400

  Salvi, R ^a   Lobarinas, E ^a   Sun, W ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE INHIBITOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ACAMPROSATE; ALPRAZOLAM; AM 101; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATORVASTATIN; CARBAMAZEPINE; CAROVERINE; CLONAZEPAM; DIAZEPAM; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FUROSEMIDE; GABAPENTIN; GACYCLIDINE; LIDOCAINE; MELATONIN; MEMANTINE; MISOPROSTOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERAMEXANE; NORTRIPTYLINE; PAROXETINE; POTASSIUM CHANNEL AFFECTING AGENT; PROSTAGLANDIN E1 DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPASMIUM R; SULPIRIDE; TIAGABINE; TRAZODONE; TRIMIPRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VARDENAFIL; VIGABATRIN; ZINC;

CLINICAL TRIAL; DEPRESSION; DIET SUPPLEMENTATION; ECONOMIC ASPECT; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; OFF LABEL DRUG USE; REVIEW; SLEEP DISORDER; TINNITUS;

EID: 76649097664     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.05.1362442     Document Type: Review

References (321)

1. Demeester, K., van Wieringen, A., Hendrickx, J.J. et al. Prevalence of tinnitus and audiometric shape. B-ENT 2007, 3(Suppl. 7): 37-49.
2. Hannaford, P.C., Simpson, J.A., Bisset, A.F., Davis, A., McKerrow, W., Milts, R. The prevalence of ear, nose and throat problems in the community: Results from a national cross-sectional postal survey in Scotland. Fam Pract 2005, 22(3): 227-33.
3. Coles, R.R. Epidemiology of tinnitus: (1) Prevalence. J Laryngol Otol Suppl 1984, 9: 7-15.
4. McCombe, A., Baguley, D., Coles, R., McKenna, L., McKinney, C., Windle-Taylor, P. Guidelines for the grading of tinnitus severity: The results of a working group commissioned by the British Association of Otolaryngologists, Head and Neck Surgeons, 1999. Clin Otolaryngol Allied Sci 2001, 26(5): 388-93.
5. Medical Research Council's Institute of Hearing Research. Epidemiology of tinnitus. In: Tinnitus. Hazell, J.W.P. (Ed.) Churchill Livingstone: Edinburgh, 1987, 46-70.
6. Hoffmann, H.J., Reed, G.W. Epidemiology of tinnitus. In: Tinnitus: Theory and Management. Snow, J.B. (Ed.). B.C. Decker; Hamilton, 2004, 16-41.
7. Davis, A., Fafaie, E. Epidemiology of tinnitus. In: Tinnitus Handbook. Tyler, R. (Ed.) Singular Publishing Group: San Diego, 2000, 1-23.
8. Axelsson, A., Ringdahl, A. Tinnitus - A study of its prevalence and characteristics. Br J Audiol 1989, 23(1): 53-62.
9. Vio, M.M., Holme, R.H. Hearing loss and tinnitus: 250 Million people and a US$10 billion potential market. Drug Discov Today 2005, 10(19): 1263-5.
10. Cave, K.M., Cornish, E.M., Chandler, D.W. Blast injury of the ear. Clinical update from the global war on terror. Mil Med 2007, 172(7): 726-30.
11. Nicolas-Puel, C., Faulconbridge, R.L., Guitton, M., Puel, J.L., Mondain, M., Uziel, A. Characteristics of tinnitus and etiology of associated hearing loss: A study of 123 patients. Int Tinnitus J 2002, 8(1): 37-44.
12. Douek, E. Classification of tinnitus. In: Tinnitus. Ciba Foundation Symposium 85. Evered, D., Lawrenson, G. (Ed.). Pitman: Bath, 1981, 4-15.
13. Moller, A.R. Tinnitus: Presence and future. Prog Brain Res 2007, 166: 3-16.
14. Meikle, M.B., Griest, S. Asymmetry in tinnitus perception. In: Tinnitus 91: Proceedings of the Fourth International Tinnitus Seminar. Aran, J.M., Dauman, R. (Ed.). Kugler Publications: Amsterdam, 1992, 231-7.
15. Hallberg, L.R., Erlandsson, S.I. Tinnitus characteristics in tinnitus complainers and noncomplainers. Br J Audiol 1993, 27(1): 19-27.
16. Tyler, R.S. The psychoacoustical measurement of tinnitus. In: Tinnitus Handbook. Tyler, R.S. (Ed.). Singular Publishing, San Diego, 2000, 149-79.
17. Loeb, M., Smith, R. Relation of induced tinnitus to physical characteristics of the inducing stimuli. J Acoust Soc Am 1967, 42(2): 453-5.
18. Norena, A., Micheyl, C., Chery-Croze, S., Collet, L. Psychoacoustic characterization of the tinnitus spectrum: Implications for the underlying mechanisms of tinnitus. Audiol Neurootol 2002, 7(6): 358-69.
19. Kaltenbach, J.A. Neurophysiology mechanisms of tinnitus. J Am Acad Audiol 2000, 11(3): 125-37.
20. Stouffer, J.L., Tyler, R.S. Characterization of tinnitus by tinnitus patients. J Speech Hear Res 1990, 55(3): 439-53.
21. Wegel, R.L., Lane, C.E. The auditory masking of one pure tone by another and its probable relation to the dynamics of the inner ear. Physical Rev 1924, 23(2): 266-85.
22. Vernon, J., Meikle, M. Tinnitus masking: Unresolved problems. Tinnitus, CIBA Foundation Symposium 85. Pittman: Bath, 1981, 239-62.
23. Henry, J.A., Rheinsburg, B., Owens, K.K., Ellingson, R.M. New instrumentation for automated tinnitus psychoacoustic assessment. Acta Otolaryngol Suppl 2006, (556): 34-8.
24. Davis, P.B., Paki, B., Hanley, P.J. Neuromonics Tinnitus Treatment: Third clinical trial. Ear Hear 2007, 28(2): 242-59.
25. Teggi, R., Bellini, C., Piccioni, L.O., Palonta, F., Bussi, M. Transmeatal low-level laser therapy for chronic tinnitus with cochlear dysfunction. Audiol Neurootol 2008, 14(2): 115-20.
26. Johnson, R.M., Brummett, R., Schleuning, A. Use of alprazolam for relief of tinnitus. A double-blind study. Arch Otolaryngol Head Neck Surg 1993, 119(8): 842-5.
27. Westerberg, B.D., Roberson, J.B. Jr., Stach, B.A. A double-blind placebo-controlled trial of baclofen in the treatment of tinnitus. Am J Otol 1996, 17(6): 896-903.
28. Penner, M.J., Zhang, T. Masking patterns for partially masked tinnitus. Int Tinnitus J 1996, 2:105-9.
29. Feldmann, H. Homolateral and contralateral masking of tinnitus by noise-bands and by pure tones. Audiology 1971, 10(3): 138-44.
30. Zwislocki, J.J., Buining, E., Glantz, J. Frequency distribution of central masking. J Acoust Soc Am 1968, 43(6): 1267-71.
31. Tyler, R.S., Babin, R., Niebuhr, D. Some observations on the masking and postmasking effects on tinnitus. J Laryngol Otol Suppl 1984, 9: 150-6.
32. Penner, MJ. Masking of tinnitus and central masking. J Speech Hear Res 1987, 30(2): 147-52.
33. Penner, M.J., Brauth, S., Hood, L. The temporal course of the masking of tinnitus as a basis for inferring its origin. J Speech Hear Res 1981, 24(2): 257-61.
34. Penner, M.J., Bilger, R.C. Adaptation and the masking of tinnitus. J Speech Hear Res 1989, 32(2): 339-46.
35. Wilson, P.H., Henry, J., Bowen, M., Haralambous, G. Tinnitus reaction questionnaire: Psychometric properties of a measure of distress associated with tinnitus. J Speech Hear Res 1991, 34(1): 197-201.
36. Kuk, F.K., Tyler, R.S., Russell, D., Jordan, H. The psychometric properties of a tinnitus handicap questionnaire. Ear Hear 1990, 11(6): 434-42.
37. Newman, C.W., Jacobson, G.P., Spitzer, J.B. Development of the Tinnitus Handicap Inventory. Arch Otolaryngol Head Neck Surg 1996, 122(2): 143-8.
38. Baguley, D.M., Andersson, G. Factor analysis of the Tinnitus Handicap Inventory. Am J Audiot 2003, 12(1): 31-4.
39. Setigmann, H., Podoshin, L, Ben-David, J., Fradis, M., Goldsher, M. Drug-induced tinnitus and other hearing disorders. Drug Safety 1996, 14(3): 198-212.
40. Briner, W. A behavioral nosology for tinnitus. Psychol Rep 1995, 77(1): 27-34.
41. Tyler, R., Coelho, C., Tao, P., Ji, H., Noble, W., Gehringer, A., Gogel, S. Identifying tinnitus subgroups with cluster analysis. Am J Audiol 2008, 17(2): S176-84.
42. Goldstein, B., Shulman, A. Tinnitus classification: Medical audiologic assessment. J Laryngol Otol - Suppl 1981, (4): 33-8.
43. Norena, A., Cransac, H., Chery-Croze, S. Towards an objectification by classification of tinnitus. Clin Neurophysiol 1999, 110(4): 666-75.
44. Levine, R.A. Typewriter tinnitus: A carbamazepine-responsive syndrome related to auditory nerve vascular compression. ORL J Otorhinolaryngol Relat Spec 2006, 68(1): 43-6; discussion 46-7.
45. Mardini, M.K. Ear-clicking "tinnitus" responding to carbamazepine. N Engl J Med 1987, 317(24): 1542.
46. Rahko, T., Hakkinen, V. Carbamazepine in the treatment of objective myoclonus tinnitus. J Laryngol Otot 1979, 93(2): 123-7.
47. Shea, J.J., Harell, M. Management of tinnitus ourium with lidocaine and carbamazepine. Laryngoscope 1978, 88(9, Pt. 1): 1477-84.
48. Dobie, R.A. A review of randomized clinical trials in tinnitus. Laryngoscope 1999, 109(8): 1202-11.
49. Dobie, R.A. Clinical trials and drug therapy for tinnitus. In: Tinnitus: Theory and Management. Snow, J.B.J. (Ed.). BC Decker, Inc.: Hamilton, 2004, 266-77.
50. Robinson, S., Viirre, E.S., Stein, M.B. Antidepressant therapy for tinnitus. In: Tinnitus: Theory and Management. Snow, J.B.J. (Ed.). BC Decker, Inc.: Hamilton, 2004, 278-93.
51. Lobarinas, E., Yang, G., Sun, W. et al. Salicylate- and quinine-induced tinnitus and effects of memantine. Acta Otolaryngol Suppl 2006, (556): 13-9.
52. Lobarinas, E., Sun, W., Cushing, R., Salvi, R. A novel behavioral paradigm for assessing tinnitus using schedule-induced polydipsia avoidance conditioning (SIP-AC). Hear Res 2004, 190(1-2): 109-14.
53. Jastreboff, P.J., Brennan, J.F., Sasaki, C.T. An animal model for tinnitus. Laryngoscope 1988, 98(3): 280-6.
54. Jastreboff, P.J., Brennan, J.F., Sasaki, C.T. Quinine-induced tinnitus in rats. Arch Otolaryngol Head Neck Surg 1991, 117(10): 1162-6.
55. Grigor, R.R., Spitz, P.W., Furst, D.E. Salicylate toxicity in elderly patients with rheumatoid arthritis. J Rheumatol 1987, 14(1): 60-6.
56. Bateman, D.N., Dyson, E.H. Quinine toxicity. Adverse Drug React Acute Poisoning Rev 1986, 5(4): 215-33.
57. Dodson, K.M., Sismanis, A. lntratympanic perfusion for the treatment of tinnitus. Otolaryngol Clin North Am 2004, 37(5): 991-1000.
58. Schwab, B., Lenarz, T., Heermann, R. Use of the round window micro cath for inner ear therapy - Results of a placebo-con trolled, prospective study on chronic tinnitus. Laryngorhinootologie 2004, 83(3): 164-72.
59. Tsai, G., Coyle, J.T. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med 1998, 49: 173-84.
60. Williams, S.H. Medications for treating alcohol dependence. Am Fam Physician 2005, 72(9): 1775-80.
61. Mason, B.J., Crean, R. Acamprosate in the treatment of alcohol dependence: Clinical and economic considerations. Expert Rev Neurother 2007, 7(11): 1465-77.
62. Pierrefiche, O., Daoust, M., Naassila, M. Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuropharmacology 2004, 47(1): 35-45.
63. Madamba, S.G., Schweitzer, P., Zieglgansberger, W., Siggins, G.R. Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro. Alcohol Clin Exp Res 1996, 20(4): 651-8.
64. Berton, F., Francesconi, W.G., Madamba, S.G., Zieglgansberger, W., Siggins, G.R. Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol Clin Exp Res 1998, 22(1): 183-91.
65. Naassila, M., Hammoumi, S., Legrand, E., Durbin, P., Daoust, M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 1998, 22(4): 802-9.
66. Zeise, M.L., Kasparov, S., Capogna, M., Zieglgansberger, W. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: Possible involvement of excitatory amino acid receptors. Eur J Pharmacol 1993, 231(1): 47-52.
67. Wu, J.Y., Jin, H., Schloss, J.V., Faiman, M.D., Ningaraj, N.S., Foos, T., Chen, W. Neurotoxic effect of acamprosate, n-acetyl-homotaurine, in cultured neurons. J Biomed Sci 2001, 8(1): 96-103.
68. Azevedo, A.A., Figueiredo, R.R. Tinnitus treatment with acamprosate: Double-blind study. Braz J Otorhinolaryngol 2005, 71(5): 618-23.
69. Azevedo, A.A., Figueiredo, R.R. Treatment of tinnitus with acamprosate. Prog Brain Res 2007, 166:273-7.
70. Oestreicher, E., Arnold, W., Ehrenberger, K., Felix, D. Memantine suppresses the glutamatergic neurotransmission of mammalian inner hair cells. ORL J Otorhinolaryngol Relat Spec 1998, 60(1): 18-21.
71. Guitton, M.J., Pujol, R., Puel, J.L. m-Chlorophenylpiperazine exacerbates perception of salicylate-induced tinnitus in rats. Eur J Neurosci 2005, 22(10): 2675-8.
72. Milbrandt, J.C., Holder, T.M., Wilson, M.C., Salvi, R.J., Caspary, D.M. GAD levels and muscimol binding in rat inferior colliculus following acoustic trauma. Hear Res 2000, 147(1-2): 251-60.
73. Brozoski, T.J., Spires, T.J., Bauer, C.A. Vigabatrin, a GABA transaminase inhibitor, reversibly eliminates tinnitus in an animal model. J Assoc Res Otolaryngol 2007, 8(1): 105-18.
74. Daftary, A., Shulman, A., Strashun, A.M., Gottschalk, C., Zoghbi, S.S., Seibyt, J.P. Benzodiazepine receptor distribution in severe intractable tinnitus. Int Tinnitus J 2004, 10(1): 17-23.
75. Suneja, S.K., Potashner, S.J., Benson, C.G. Plastic changes in glycine and GABA release and uptake in adult brain stem auditory nuclei after unilateral middle ear ossicle removal and cochlear ablation. Exp Neurol 1998, 151(2): 273-88.
76. Kudo, Y., Shibata, S. Effects of caroverine and diltiazem on synaptic responses, L-glutamate-induced depolarization and potassium efflux in the frog spinal cord. Br J Pharmacol 1984, 83(3): 813-20.
77. Koppi, S., Eberhardt, G., Haller, R., Konig, P. Calcium-channel- blocking agent in the treatment of acute alcohol withdrawal -Caroverine versus meprobamate in a randomized double-blind study. Neuropsychobiology 1987, 17(1-2): 49-52.
78. Saletu, B., Grunberger, J., Anderer, P., Linzmayer, L., Konig, P. Acute central effects of the calcium channel blocker and antiglutamatergic drug caroverine. Double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration. Arzneimittelforschung 1995, 45(3): 217-29.
79. Ehrenberger, K., Felix, D. Receptor pharmacological models for inner ear therapies with emphasis on glutamate receptors: A survey. Acta Otolaryngol (Stockh) 1995, 115(2): 236-40.
80. Ehrenberger, K., Felix, D. Caroverine depresses the activity of cochlear glutamate receptors in guinea pigs: In vivo model for drug-induced neuroprotection? Neuropharmacology 1992, 31(12): 1259-63.
81. Chen, Z., Duan, M., Lee, H., Ruan, R., Ulfendahl, M. Pharmacokinetics of caroverine in the inner ear and its effects on cochlear function after systemic and local administrations in guinea pigs. Audiol Neurootol 2003, 8(1): 49-56.
82. Denk, D.M., Heinzl, H., Franz, P., Ehrenberger, K. Caroverine in tinnitus treatment. A placebo-controlled blind study. Acta Otolaryngol 1997, 117(6): 825-30.
83. Guitton, M.J., Caston, J., Ruel, J., Johnson, R.M., Pujol, R., Puel, J.L. Salicylate induces tinnitus through activation of cochlear NMDA receptors. J Neurosci 2003, 23(9): 3944-52.
84. Guitton, M.J., Dudai, Y. Blockade of cochlear NMDA receptors prevents long-term tinnitus during a brief consolidation window after acoustic trauma. Neural Plast 2007, 2007: 80904.
85. Duckert, L.G., Rees, T.S. Placebo effect in tinnitus management. Otolaryngol Head Neck Surg 1984, 92(6): 697-9.
86. Domeisen, H., Hotz, M.A., Hausler, R. Caroverine in tinnitus treatment. Acta Otolaryngol 1998, 118(4): 606-8.
87. Peskind, E.R., Potkin, S.G., Pomara, N., Ott, B.R., Graham, S.M., Olin, J.T., McDonald, S. Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006, 14(8): 704-15.
88. Muhonen, L.H., Lonnqvist, J., Juva, K., Alho, H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008, 69(3): 392-9.
89. Rogawski, M.A., Wenk, G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 2003, 9(3): 275-308.
90. Deshpande, S.S., Smith, C.D., Filbert, M.G. Assessment of primary neuronal culture as a model for soman-induced neurotoxicity and effectiveness of memantine as a neuroprotective drug. Arch Toxicol 1995, 69(6): 384-90.
91. Rammes, G., Rupprecht, R., Ferrari, U., Zieglgansberger, W., Parsons, C.G. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 2001, 306(1-2): 81-4.
92. Oliver, D., Ludwig, J., Reisinger, E., Zoellner, W., Ruppersberg, J.P., Fakler, B. Memantine inhibits efferent cholinergic transmission in the cochlea by blocking nicotinic acetylcholine receptors of outer hair cells. Mol Pharmacol 2001, 60(1): 183-9.
93. Jastreboff, P.J., Brennan, J.F., Coleman, J.K., Sasaki, C.T. Phantom auditory sensation in rats: An animal model for tinnitus. Behav Neurosci 1988, 102(6): 811-22.
94. Myers, E.N., Bernstein, J.M. Salicylate ototoxicity; a clinical and experimental study. Arch Otolaryngol 1965, 82(5): 483-93.
95. Peng, B.G., Chen, S., Lin, X. Aspirin selectively augmented N-methyl-D-aspartate types of glutamate responses in cultured spiral ganglion neurons of mice. Neurosci Lett 2003, 343(1): 21-4.
96. Figueiredo, R.R., Langguth, B., Mello de Oliveira, P., Aparecida de Azevedo, A. Tinnitus treatment with memantine. Otolaryngol Head Neck Surg 2008, 138(4): 492-6.
97. Gilling, K., Jatzke, C., Wollenburg, C., Vanejevs, M., Kauss, V., Jirgensons, A., Parsons, C.G. A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists - In vitro characterization. J Neural Transm 2007, 114(12): 1529-37.
98. Plazas, P.V., Savino, J., Kracun, S. et al. Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors. Eur J Pharmacol 2007, 566(1-3): 11-9.
99. Wenzel, G.I., Lim, H.H., Stöver, T., Lobl, T., Schloss, J., Schwab, B., Lenarz, T. Effects of gacyclidine extracochlear perfusion on tinnitus in humans and intracochlear perfusion on ABR thresholds in guinea pigs. Abstr Assoc Res Otolaryngol 2007, 30: 23-4.
100. Srisurapanont, M., Boonyanaruthee, V. Alprazolam and standard antidepressants in the treatment of depression: A meta-analysis of the antidepressant effect. J Med Assoc Thai 1997, 80(3): 183-8.
101. Kravitz, H.M., Fawcett, J., Newman, A.J. Alprazolam and depression: A review of risks and benefits. J Clin Psychiatry 1993, 54(SuppL): 78-84; discussion 85.
102. Freeman, A.M. 3rd, Fleece, L., Folks, D.G. et al. Alprazolam treatment of postcoronary bypass anxiety and depression. J Clin Psychopharmacol 1986, 6(1): 39-41.
103. Dunner, D.L., lshiki, D., Avery, D.H., Wilson, L.G., Hyde, T.S. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. J Clin Psychiatry 1986, 47(9): 458-60.
104. Obata, T., Yamamura, H.I. Modulation of GABA-stimulated chloride influx into membrane vesicles from rat cerebral cortex by triazolobenzodiazepines. Life Sci 1988, 42(6): 659-65.
105. Lopez, F., Miller, L.G., Greenblatt, D.J., Schatzki, A., Lumpkin, M., Shader, R.I. Chronic low-dose alprazolam augments gamma-aminobutyric acid(A) receptor function. J Clin Psychopharmacol 1992, 12(2): 119-23.
106. Huynh, L., Fields, S. Alprazolam for tinnitus. Ann Pharmacother 1995, 29(3): 311-2.
107. Sieghart, W. Pharmacology of benzodiazepine receptors: An update. J Psychiatry Neurosci 1994, 19(1): 24-9.
108. McLean, M.J., Macdonald, R.L. Benzodiazepines, but not beta carbolines, limit high frequency repetitive firing of action potentials of spinal cord neurons in cell culture. J Pharmacol Exp Ther 1988, 244(2): 789-95.
109. Kay, N.J. Oral chemotherapy in tinnitus. Br J Audiol 1981, 15(2): 123-4.
110. Busto, U., Fornazzari, L., Naranjo, C.A. Protracted tinnitus after discontinuation of long-term therapeutic use of benzodiazepines. J Clin Psychopharmacol 1988, 8(5): 359-62.
111. Busto, U., Sellers, E.M., Naranjo, C.A., Cappell, H., Sanchez-Craig, M., Sykora, K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986, 315(14): 854-9.
112. Gananca, M.M., Caovilla, H.H., Gananca, F.F., Gananca, C.F., Munhoz, M.S., da Silva, M.L., Serafini, F. Clonazepam in the pharmacological treatment of vertigo and tinnitus. Int Tinnitus J 2002, 8(1): 50-3.
113. Bahmad, F.M. Jr., Venosa, A.R., Oliveira, C.A. Benzodiazepines and GABAergics in treating severe disabling tinnitus of predominantly cochlear origin. Int Tinnitus J 2006, 12(2): 140-4.
114. Murai, K., Tyler, R.S., Harker, L.A., Stouffer, J.L. Review of pharmacologic treatment of tinnitus. Am J Otol 1992, 13(5): 454-64.
115. Mattson, R.H., Petroff, O.A., Rothman, D., Behar, K. Vigabatrin: Effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Acta Neurol Scand Suppl 1995, 162: 27-30.
116. Richens, A. Pharmacology and clinical pharmacology of vigabatrin. J Child Neurol 1991, Suppl. 2: S7-10.
117. Czuczwar, S.J., Patsalos, P.N. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001, 15(5): 339-50.
118. Wu, Y., Wang, W., Richerson, G.B. Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release. J Neurophysiol 2003, 89(4): 2021-34.
119. Smith, S.E., Parvez, N.S., Chapman, A.G., Meldrum, B.S. The gamma-aminobutyric acid uptake inhibitor, tiagabine, is anticonvulsant in two animal models of reflex epilepsy. Eur J Pharmacol 1995, 273(3): 259-65.
120. Adkins, J.C., Noble, S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998, 55(3): 437-60.
121. Zwanzger, P., Rupprecht, R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci 2005, 30(3): 167-75.
122. Gram, L. Tiagabine: A novel drug with a GABAergic mechanism of action. Epilepsia 1994, 35(Suppl. 5): S85-7.
123. Chen, L, Yung, W.H. Effects of the GABA-uptake inhibitor tiagabine in rat globus pallidus. Exp Brain Res 2003, 152(2): 263-9.
124. Potashner, S.J., Suneja, S.K., Benson, C.G. Regulation of D-aspartate release and uptake in adult brain stem auditory nuclei after unilateral middle ear ossicle removal and cochlear ablation. Exp Neurol 1997, 148(1): 222-35.
125. Caspary, D.M., Ling, L., Turner, J.G., Hughes, L.F. Inhibitory neurotransmission, plasticity and aging in the mammalian central auditory system. J Exp Biol 2008, 211(Pt. 11): 1781-91.
126. Bauer, C.A., Brozoski, T.J., Holder, T.M., Caspary, D.M. Effects of chronic salicylate on GABAergic activity in rat inferior colliculus. Hear Res 2000, 147(1-2): 175-82.
127. Besag, F.M. Behavioural effects of the newer antiepileptic drugs: An update. Expert Opin Drug Saf 2004, 3(1): 1-8.
128. Schwartz, M.L., Meyer, M.B., Covino, B.G., Narang, R.M., Sethi, V., Schwartz, A.J., Kamp, P. Antiarrhythmic effectiveness of Intramuscular lidocaine: Influence of different injection sites. J Clin Pharmacol 1974, 14(2): 77-83.
129. Clarkson, C.W., Follmer, C.H., Ten Eick, R.E., Hondeghem, L.M., Yeh, J.Z. Evidence for two components of sodium channel block by lidocaine in isolated cardiac myocytes. Circ Res 1988, 63(5): 869-78.
130. Courtney, K.R. Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol Exp Ther 1975, 195(2): 225-36.
131. Lenkowski, P.W., Shah, B.S., Dinn, A.E., Lee, K., Patel, M.K. Lidocaine block of neonatal Nav1.3 is differentially modulated by co-expression of beta1 and beta3 subunits. Eur J Pharmacol 2003, 467(1-3): 23-30.
132. Josephson, I.R. Lidocaine blocks Na, Ca and K currents of chick ventricular myocytes. J Mol Cell Cardiol 1988, 20(7): 593-604.
133. Yu, M., Chen, L. Modulation of major voltage- and ligand-gated ion channels in cultured neurons of the rat inferior colliculus by lidocaine. Acta Pharmacol Sin 2008, 29(12): 1409-18.
134. Barany, R. Die Beinflussung des Ohrensausens durch intravenös injizierte Lokalanaestetica. Acta Otolaryngol 1935, 23: 201-3.
135. Melding, P.S., Goodey, R.J., Thorne, P.R. The use of intravenous lignocaine in the diagnosis and treatment of tinnitus. J Laryngol Otol 1978, 92(2): 115-21.
136. Martin, F.W., Colman, B.H. Tinnitus: A double-blind crossover controlled trial to evaluate the use of lignocaine. Clin Otolaryngol 1980, 5(1): 3-11.
137. Sanchez, T.G., Balbani, A.P., Bittar, R.S., Bento, R.F., Camara, J. Lidocaine test in patients with tinnitus: Rationale of accomplishment and relation to the treatment with carbamazepine. Auris Nasus Larynx 1999, 26(4): 411-7.
138. Duckert, L.G., Rees, T.S. Treatment of tinnitus with intravenous lidocaine: A double-blind randomized trial. Otolaryngol Head Neck Surg 1983, 91(5): 550-5.
139. Reyes, S.A., Salvi, R.J., Burkard, R.F., Coad, M.L., Wack, D.S., Galantowicz, P.J., Lockwood, A.H. Brain imaging of the effects of lidocaine on tinnitus. Hear Res 2002, 171(1-2): 43-50.
140. Kallio, H., Niskanen, M.L., Havia, M., Neuvonen, P.J., Rosenberg, P.H., Kentala, E. I.V. ropivacaine compared with lidocaine for the treatment of tinnitus. Br J Anaesth 2008, 101(2): 261-5.
141. Haginomori, S., Makimoto, K., Araki, M., Kawakami, M., Takahashi, H. Effect of lidocaine injection of EOAE in patients with tinnitus. Acta Otolaryngol 1995, 115(4): 488-92.
142. Baguley, D.M., Jones, S., Wilkins, I., Axon, P.R., Moffat, D.A. The inhibitory effect of intravenous lidocaine infusion on tinnitus after translabyrinthine removal of vestibular schwannoma: A double-blind, placebo-controlled, crossover study. Otol Neurotol 2005, 26(2): 169-76.
143. Cathcart, J.M. Assessment of the value of tocainide hydrochloride in the treatment of tinnitus. J Laryngol Otol 1982, 96(11): 981-4.
144. Hulshof, J.H., Vermeij, P. The value of tocainide in the treatment of tinnitus. A double-blind controlled study. Arch Oto-Rhino-Laryngol 1985, 241(3): 279-83.
145. Emmett, J.R., Shea, J.J. Treatment of tinnitus with tocainide hydrochloride. Otolaryngology Head Neck Surg 1980, 88(4): 442-6.
146. Blayney, A.W., Phillips, M.S., Guy, A.M., Colman, B.H. A sequential double blind cross-over trial of tocainide hydrochloride in tinnitus. Clin Otolaryngol 1985, 10(2): 97-101.
147. Lenarz, T. Treatment of tinnitus with lidocaine and tocainide. Scand Audiol Suppl 1986, 26: 49-51.
148. Gribkoff, V.K. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets 2003, 7(6): 737-48.
149. Korsgaard, M.P., Hartz, B.P., Brown, W.D., Ahring, P.K., Strobaek, D., Mirza, N.R. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J Pharmacol Exp Ther 2005, 314(1): 282-92.
150. Lobarinas, E., Dalby-Brown, W., Stolzberg, D., Mirza, N., Salvi, R. Effects of the BK agonists BMS-204352 and the enantiomeric compound ("Renantiomer") on transient, salicylate induced tinnitus in rats. Assoc Res Otolarygol (Baltimore) 2009.
151. Munro, G., Erichsen, H.K., Mirza, N.R. Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. Neuropharmacology 2007, 53(5): 609-18.
152. Israel, M., Beaudry, P. Carbamazepine in psychiatry: A review. Can J Psychiatry 1988, 33(7): 577-84.
153. Hirschfeld, R.M., Kasper, S. A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 2004, 7(4): 507-22.
154. Cereghino, J.J., Brock, J.T., Van Meter, J.C., Penry, J.K., Smith, L.D., White, B.G. The efficacy of carbamazepine combinations in epilepsy. Clin Pharmacol Ther 1975, 18(06): 733-41.
155. Taylor, J.C., Brauer, S, Espir, M. L. Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J 1981, 57(663): 16-8.
156. Herrera, J.M., Sramek, J.J., Costa, J F. Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia. Drug lntell Clin Pharm 1987, 21(4): 355-8.
157. Willow, M., Gonoi, T., Catterall, W.A. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol Pharmacol 1985, 27(5): 549-558.
158. Kuo, C.C., Chen, R.S., Lu, L., Chen, R.C. Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from Phenytoin and possible therapeutic implications. Mol Pharmacol 1997, 51(6): 1077-83.
159. Cardenas, C.A., Cardenas, C.G., de Armendi, A.J., Scroggs, R.S. Carbamazepine interacts with a slow inactivation state of NaV1.8-like sodium channels. Neurosci Lett 2006, 408(2): 129-34.
160. Dailey, J.W., Reith, M.E., Steidley, K.R., Milbrandt, J.C., Jobe, P.C. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia 1998, 39(10): 1054-63.
161. Zona, C., Tancredi, V., Palma, E., Pirrone, G.C., Avoli, M. Potassium currents in rat cortical neurons in culture are enhanced by the antiepileptic drug carbamazepine. Can J Physiol Pharmacol 1990, 68(4): 545-7.
162. Ambrosio, A.F., Silva, A.P., Malva, J.O., Soares-da-Silva, P., Carvalho, A.P., Carvalho, C.M. Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology 1999, 38(9): 1349-59.
163. Donaldson, I. Tegretol: A double blind trial in tinnitus. J Laryngol Otol 1981, 95(9): 947-51.
164. Hulshof, J.H., Vermeij, P. The value of carbamazepine in the treatment of tinnitus. ORL J Otorhinolaryngol Relat Spec 1985, 47(5): 262-6.
165. Marks, N.J., Onisiphorou, C., Trounce, J.R. The effect of single doses of amylobarbitone sodium and carbamazepine in tinnitus. J Laryngol Otol 1981, 95(9): 941-5.
166. Melding, P.S., Goodey, R.J. The treatment of tinnitus with oral anticonvulsants. J Laryngol Otol 1979, 93(2): 111-22.
167. Zheng, Y., Hooton, K., Smith, P.F., Darlington, C.L. Carbamazepine reduces the behavioural manifestations of tinnitus following salicylate treatment in rats. Acta Otolaryngol 2008, 128(1): 48-52.
168. Liu, J., Li, X., Wang, L., Dong, Y., Han, H., Liu, G. Effects of salicylate on serotoninergic activities in rat inferior colliculus and auditory cortex. Hear Res 2003, 175(1-2): 45-53.
169. Liu, Y., Zhang, H., Li, X. et al. Inhibition of voltage-gated channel currents in rat auditory cortex neurons by salicylate. Neuropharmacology 2007, 53(7): 870-80.
170. Wang, H.T., Luo, B., Zhou, K.Q., Xu, T.L., Chen, L. Sodium salicylate reduces inhibitory postsynaptic currents in neurons of rat auditory cortex. Hear Res 2006, 215(1-2): 77-83.
171. Menkes, D.B., Larson, P.M. Sodium valproate for tinnitus. J Neurol Neurosurg Psychiatry 1998, 65(5): 803.
172. Reeves, R.R., Mustain, D.W., Pendarvis, J.E. Valproate-induced tinnitus misinterpreted as psychotic symptoms. South Med J 2000, 93(10): 1030-1.
173. Goodey, R. Drug treatment for tinnitus. Prog Brain Res 2007, 166: 237-46.
174. Sivenius, J., Kalviainen, R., Ylinen, A., Riekkinen, P. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991, 32(4): 539-42.
175. Levendoglu, F., Ogun, C.O., Ozerbil, O., Ogun, T.C., Ugurlu, H. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine 2004, 29(7): 743-51.
176. Smith, D.G., Ehde, D.M., Hanley, M.A. et al. Efficacy of gabapentin in treating chronic phantom limb and residual limb pain. J Rehabil Res Dev 2005, 42(5): 645-54.
177. Di Trapani, G., Mei, D., Marra, C., Mazza, S., Capuano, A. Gabapentin in the prophylaxis of migraine: A double-blind randomized placebo-con-trolled study. Clin Ter 2000, 151(3): 145-8.
178. Goa, K.L., Sorkin, E.M. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993, 46(3): 409-27.
179. Rock, D.M., Kelly, K.M., Macdonald, R.L. Gabapentin actions on ligandand voltage-gated responses in cultured rodent neurons. Epilepsy Res 1993, 16(2): 89-98.
180. Honmou, O., Kocsis, J.D., Richerson, G.B. Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro. Epilepsy Res 1995, 20(3): 193-202.
181. Petroff, O.A., Rothman, D.L., Behar, K.L., Lamoureux, D., Mattson, R.H. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996, 39(1): 95-9.
182. Hendrich, J., Van Minh, A.T., Heblich, F. et al. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci USA 2008, 105(9): 3628-33.
183. Zapp, J.J. Gabapentin for the treatment of tinnitus: A case report. Ear Nose Throat J 2001, 80(2): 114-6.
184. Shulman, A. Gabapentin and tinnitus relief. Int Tinnitus J 2008, 14(1): 1-5.
185. Bauer, C.A., Brozoski, T.J. Assessing tinnitus and prospective tinnitus therapeutics using a psychophysical animal model. J Assoc Res Otolaryngol 2001, 2(1): 54-64.
186. Witsell, D.L., Hannley, M.T., Stinnet, S., Tucci, D.L. Treatment of tinnitus with gabapentin: A pilot study. Otol Neurotol 2007, 28(1): 11-5.
187. Bakhshaee, M., Ghasemi, M., Azarpazhooh, M., Khadivi, E., Rezaei, S., Shakeri, M., Tale, M. Gabapentin effectiveness on the sensation of subjective idiopathic tinnitus: A pilot study. Eur Arch Otorhinolaryngol 2008, 265(5): 525-30.
188. Piccirillo, J.F., Finnell, J., Vlahiotis, A., Chole, R.A., Spitznagel, E. Jr. Relief of idiopathic subjective tinnitus: Is gabapentin effective? Arch Otolaryngol Head Neck Surg 2007, 133(4): 390-7.
189. Bauer, C.A., Brozoski, T.J. Effect of gabapentin on the sensation and impact of tinnitus. Laryngoscope 2006, 116(5): 675-81.
190. Gross, G., Xin, X., Gastpar, M. Trimipramine: Pharmacological reevaluation and comparison with clozapine. Neuropharmacology 1991, 30(11): 1159-66.
191. Juorio, A.V., Li, X.M., Boulton, A.A. The effects of chronic trimipramine treatment on biogenic amine metabolism and on dopamine D2, 5-HT2 and tryptamine binding sites in rat brain. Gen Pharmacol 1990, 21(5): 759-62.
192. Mihail, R.C., Crowley, J.M., Waiden, B.E., Fishburne, J., Reinwall, J.E., Zajtchuk, J.T. The tricyclic trimipramine in the treatment of subjective tinnitus. Ann Otol Rhinol Laryngol 1988, 97(2, Pt. 1): 120-3.
193. Gracious, B., Wisner, K.L. Nortriptyline in chronic fatigue syndrome:
194. Punay, N.C., Couch, J.R. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 2003, 7(1): 51-4.
195. Atkinson, J.H., Slater, M.A., Williams, R.A. et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain 1998, 76(3): 287-96.
196. Anderson, J., Lambert, N.G., Pigott, R.V. An evaluation of fluphenazine with nortriptyline in anxiety and depression. Practitioner 1972, 208(246): 511-7.
197. Sullivan, M.D., Dobie, R.A., Sakai, C.S., Katon, W.J. Treatment of depressed tinnitus patients with nortriptyline. Ann Otol Rhinol Laryngol 1989, 98(11): 867-72.
198. Sullivan, M., Katon, W., Russo, J., Dobie, R., Sakai, C. A randomized trial of nortriptyline for severe chronic tinnitus. Effects on depression, disability, and tinnitus symptoms. Arch Intern Med 1993, 153(19): 2251-9.
199. Katon, W., Sullivan, M., Russo, J., Dobie, R., Sakai, C. Depressive symptoms and measures of disability: A prospective study. J Affect Disord 1993, 27(4): 245-54.
200. Stein, D.J., Davidson, J., Seedat, S., Beebe, K. Paroxetine in the treatment of post-traumatic stress disorder: Pooled analysis of placebo-controlled studies. Expert Opin Pharmacother 2003, 4(10): 1829-38.
201. Oehrberg, S., Christiansen, P.E., Behnke, K. et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995, 167(3): 374-9.
202. Denys, D., van der Wee, N., van Megen, H.J., Westenberg, H.G. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003, 23(6): 568-75.
203. Thomas, D.R., Nelson, D.R., Johnson, A.M. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 1987, 93(2): 193-200.
204. Hyttel, J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994, 9(Suppl. 1): 19-26.
205. Robinson, S.K., Viirre, E.S., Bailey, K.A., Gerke, M.A., Harris, J.P., Stein, M.B. Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med 2005, 67(6): 981-8.
206. Parnes, S.M. Current concepts in the clinical management of patients with tinnitus. Eur Arch Otorhinolaryngol 1997, 254(9-10): 406-9.
207. Kingery, W.S., Davies, M.F., Clark, J.D. A substance P receptor (NK1) antagonist can reverse vascular and nociceptive abnormalities in a rat model of complex regional pain syndrome type II. Pain 2003, 104(1-2): 75-84.
208. Dionne, R.A., Max, M.B., Gordon, S.M. et al. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther 1998, 64(5): 562-8.
209. Vass, Z., Nuttall, A.L., Coleman, J.K., Miller, J.M. Capsaicin-induced release of substance P increases cochlear blood flow in the guinea pig. Hear Res 1995, 89(1-2): 86-92.
210. Sun, W., Ding, D.L., Wang, P., Sun, J., Jin, X., Salvi, R.J. Substance P inhibits potassium and calcium currents in inner ear spiral ganglion neurons. Brain Res 2004, 1012(1-2): 82-92.
211. Holliday, S.M., Plosker, G.L. Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy. Drugs Aging 1993, 3(3): 278-99.
212. Kronig, M.H., Apter, J., Asnis, G. et al. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol 1999, 19(2): 172-6.
213. Hirschfeld, R.M. Sertraline in the treatment of anxiety disorders. Depress Anxiety 2000, 11(4): 139-57.
214. Hesslinger, B., Van de Loo, A., Klecha, D., Harter, M., Schmidt-Schweda, S. Depression and panic disorder after heart transplantation - Treatment with sertraline. Pharmacopsychiatry 2002, 35(1): 31-2.
215. Guthrie, S.K. Sertraline: A new specific serotonin reuptake blocker. Dicp 1991, 25(9): 952-61.
216. Schmidt, A., Lebel, L., Koe, B.K., Seeger, T., Heym, J. Sertraline potently displaces (+)-[3H]3-PPP binding to sigma sites in rat brain. Eur J Pharmacol 1989, 165(2-3): 335-6.
217. Robinson, S. Antidepressants for treatment of tinnitus. Prog Brain Res 2007, 166: 263-71.
218. Miller, M.J., Sadowska-Krowicka, H., Jeng, A.Y. et al. Substance P levels in experimental ileitis in guinea pigs: effects of misoprostol. Am J Physiol 1993, 265(2, Pt. 1): G321-30.
219. Gullikson, G.W., Anglin, C.P., Kessler, L.K., Smeach, S., Bauer, R.F., Dajani, E.Z. Misoprostol attenuates aspirin-induced changes in potential difference and associated damage in canine gastric mucosa. Clin Invest Med 1987, 10(3): 145-51.
220. Roth, S.H. Misoprostol in the prevention of NSAID-induced gastric ulcer: A multicenter, double-blind, placebo-controlled trial. J Rheumatol Suppl 1990, 20: 20-4.
221. Hall, R., Duarte-Gardea, M., Harlass, F. Oral versus vaginal misoprostol for labor induction. Obstet Gynecol 2002, 99(6): 1044-8.
222. Widomski, D., Fretland, D.J., Gasiecki, A.F., Collins, P.W. The prostaglandin analogs, misoprostol and SC-46275, potently inhibit cytokine release from activated human monocytes. Immunopharmacol Immunotoxicol 1997, 19(2): 165-74.
223. Briner, W., House, J., O'Leary, M. Synthetic prostaglandin B misoprostol as a treatment for tinnitus. Arch Otolaryngol Head Neck Surg 1993, 119(6): 652-4.
224. Akkuzu, B., Yilmaz, I., Cakmak, O., Ozluoglu, L.N. Efficacy of misoprostol in the treatment of tinnitus in patients with diabetes and/or hypertension. Auris Nasus Larynx 2004, 31(3): 226-32.
225. Naoumova, R.P., Dunn, S., Rallidis, L. et al. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res 1997, 38(7): 1496-500.
226. Gresser, U., Gathof, B.S. Atorvastatin: Gold standard for prophylaxis of myocardial ischemia and stroke - Comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res 2004, 9(1): 1-17.
227. Heinonen, T.M., Stein, E., Weiss, S.R., McKenney, J.M., Davidson, M., Shurzinske, L., Black, D.M. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: Results of a randomized, double-masked study. Clin Ther 1996,18(5): 853-63.
228. Sugiyama, M., Ohashi, M., Takase, H., Sato, K., Ueda, R., Dohi, Y. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels 2005, 20(4): 133-6.
229. Wang, H., Lynch, J.R., Song, P. et al. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol 2007, 206(1): 59-69.
230. Olzowy, B., Canis, M., Hempel, J.M., Mazurek, B., Suckfull, M. Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: Results of a prospective, randomized, double-blind clinical trial. Otol Neurotol 2007, 28(4): 455-8.
231. Wu, C.T., Wong, C.S., Yeh, C.C., Borel, C.O. Treatment of cerebral vasospasm after subarachnoid hemorrhage - A review. Acta Anaesthesiol Taiwan 2004, 42(4): 215-22.
232. Duley. L., Henderson-Smart. D.J., Meher, S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2006, 3: CD001449.
233. Scriabine, A., van den Kerckhoff, W. Pharmacology of nimodipine. A review. Ann NY Acad Sci 1988, 522: 698-706.
234. Theopold, H.M. Nimodipine (Bay e 9736) a new therapy concept in diseases of the inner ear? Laryngol Rhinol Otol 1985, 64(12): 609-13.
235. Wang, H., Jiang, S., Yang, W., Han, D. Evaluating effects of some medicine on tinnitus with animal behavioral model in rots. Zhonghua Er Bi Yan Hou Ke Za Zhi 2000, 35(5): 331-4.
236. Jastreboff, P.J., Brennan, J.F. Specific effects of nimodipine on the auditory system. Ann NY Acad Sci 1988, 522: 716-8.
237. Davies, E., Knox, E., Donaldson, I. The usefulness of nimodipine, an L-calcium channel antagonist, in the treatment of tinnitus. Br J Audiol 1994, 28(3): 125-9.
238. Hutcheon, D.E., Leonard, G. Diuretic and antihypertensive actions of furosemide. J Clin Pharmacol J New Drugs 1967, 7(1): 26-33.
239. Shiozaki, A., Miyazaki, H., Niisato, N. et al. Furosemide, a blocker of Na+/K+/2CI- cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0/G1 state. J Physiol Sci 2006, 56(6): 401-6.
240. Sakaguchi, N., Crouch, J.J., Lytle, C., Schulte, B.A. Na-K-CI cotransporter expression in the developing and senescent gerbil cochlea. Hear Res 1998, 118(1-2): 114-22.
241. Chen, H., Sun, D. The role of Na-K-CI co-transporter in cerebral ischemia. Neurol Res 2005, 27(3): 280-6.
242. Kolbaev, S.N., Sharonova, I.N., Vorobjev, V.S., Skrebitsky, V.G. Mechanisms of GABA(A) receptor blockade by millimolar concentrations of furosemide in isolated rat Purkinje cells. Neuropharmacology 2002, 42(7): 913-21.
243. Rybak, L.P., Morizono, T. Effect of furosemide upon endolymph potassium concentration. Hear Res 1982, 7(2): 223-31.
244. Risey, J.A., Guth, P.S., Amedee, R.G. Furosemide distinguishes central and peripheral tinnitus. Int Tinnitus J 1995, 1(2): 99-103.
245. Futaki, T., Kitahara, M., Morimoto, M. A comparison of the furosemide and glycerol tests for Meniere's disease. With special reference to the bilateral lesion. Acta Otolaryngol 1977, 83(3-4): 272-8.
246. Kuchar, D.L., O'Rourke, M.F. High dose furosemide in refractory cardiac failure. Eur Heart J 1985, 6(11): 954-8.
247. Ho, K.M., Sheridan, D.J. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 2006, 333(7565): 420.
248. Huic, M., Vrhovac, B., Macolic-Sarinic, V., Francetic, I., Bakran, I., Giljanovic, S. How safe are bioequivalence studies in healthy volunteers? Therapie 1996, 51(4): 410-3.
249. Wallach, D.P. Studies on the GABA pathway. I. The inhibition of gamma-aminobutyric acid-alpha-ketoglutaric acid transaminase in vitro and in vivo by U-7524 (amino-oxyacetic acid). Biochem Pharmacol 1961, 5: 323-31.
250. Kerwin, R., Pycock, C. Baclofen (beta-p-chlorophenyl-gamma- aminobutyric acid) enhances [3H]gamma-aminobutyric acid (3H-GABA) release from rat globus pallidus in vitro. J Pharm Pharmacol 1978, 30(10): 622-7.
251. Bobbin, R.P., Gondra, M.I. Effect of intracochlear aminooxyacetic acid on cochlear potentials and endolymph composition. Ann Otol Rhinol Laryngol 1975, 84(2, Pt. 1): 192-7.
252. Reed, H.T., Meltzer, J., Crews, P., Norris, C.H., Quine, D.B., Guth, P.S. Amino-oxyacetic acid as a palliative in tinnitus. Arch Otolaryngol 1985, 111(12): 803-5.
253. Guth, P.S., Risey, J., Briner, W. et al. Evaluation of amino-oxyacetic acid as a palliative in tinnitus. Ann Otol Rhinol Laryngol 1990, 99(1): 74-9.
254. McCabe, B.F. Central aspects of drugs for motion sickness and vertigo. Adv Otorhinolaryngol 1973, 20: 458-69.
255. Kranke, P., Morin, A.M., Roewer, N., Wulf, H., Eberhart, L.H. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: A quantitative systematic review. Anesth Analg 2002, 95(1): 133-43.
256. Miranda, H.F., Silva, W.I., Wolstenholme, W.W., Cuevas, N. Selective antagonism by pirenzepine and N-methyl-scopolamine on muscarinic receptor subtypes of the rat vas deferens. Gen Pharmacol 1988, 19(3): 417-20.
257. Dohanich, G.P., Johnson, A.E., Nock, B., McEwen, B.S., Feder, H.H. Distribution of cholinergic muscarinic binding sites in guinea-pig brain as determined by in vitro autoradiography of [3H]N-methyl scopolamine binding. Eur J Pharmacol 1985, 119(1-2): 9-16.
258. Metherate, R., Ashe, J.H., Weinberger, N.M. Acetylcholine modifies neuronal acoustic rate-level functions in guinea pig auditory cortex by an action at muscarinic receptors. Synapse 1990, 6(4): 364-8.
259. Whipple, M.R., Drescher, D.G. Muscarinic receptors in the cochlear nucleus and auditory nerve of the guinea pig. J Neurochem 1984, 43(1): 192-8.
260. Wallhausser-Franke, E., Cuautle-Heck, B., Wenz, G., Langner, G., Mahlke, C. Scopolamine attenuates tinnitus-related plasticity in the auditory cortex. Neuroreport 2006, 17(14): 1487-91.
261. Lobarinas, E., Sun, W., Stolzberg, D., Lu, J., Salvi, R. Human brain imaging of tinnitus and animal models. Semin Hear 2008, 29(4): 333-49.
262. Timmerman, H. Calcium modulation and clinical effect. Profile of cyclandelate. Drugs 1987, 33(Suppl. 2): 1-4.
263. Siniatchkin, M., Gerber, W.D., Vein, A. Clinical efficacy and central mechanisms of cyclandelate in migraine: A double-blind placebo-controlled study. Funt Neurol 1998, 13(1): 47-56.
264. Middleton, B., Middleton, A., White, D.A., Bell, G.D. Dietary cyclandelate decreases pre-established atherosclerosis in the rabbit. Atherosclerosis 1984, 51(2-3): 171-8.
265. Holstein, N. Ginkgo special extract EGb 761 in tinnitus therapy. An overview of results of completed clinical trials. Fortschr Med Orig 2001, 118(4): 157-64.
266. Huang, M.H., Huang, C.C., Ryu, S.J., Chu, N.S. Sudden bilateral hearing impairment in vertebrobasilar occlusive disease. Stroke 1993, 24(1): 132-7.
267. Memin, Y. Perceived efficacy of cyclandelate in the treatment of cochleovestibular and retinal disturbances related to cerebrovascular insufficiency. A study in general practice comprising 2772 patients. Drugs 1987, 33(Suppl. 2): 120-4.
268. Hester, T.O., Theilman, G., Green, W., Jones, R.O. Cyclandelate in the management of tinnitus: A randomized, placebo- controlled study. Otolaryngol Head Neck Surg 1998, 118(3, Pt. 1): 329-32.
269. Memo, M., Battaini, F., Spano, P.F., Trabucchi, M. Sulpiride and the role of dopaminergic receptor blockade in the antipsychotic activity of neuroleptics. Acta Psychiatr Scand 1981, 63(4): 314-24.
270. Imafuku, J. The characterization of [3H]sulpiride binding sites in rat striatal membranes. Brain Res 1987, 402(2): 331-8.
271. Jastreboff, P.J., Hazell, J.W.P. A neurophysiological approach to tinnitus: Clinical implications. Br J Audiol 1993, 27(1): 7-17.
272. Lockwood, A.H., Salvi, R.J., Coad, M.L., Towsley, M.L., Wack, D.S., Murphy, B.W. The functional neuroanatomy of tinnitus: Evidence for limbic system links and neural plasticity. Neurology 1998, 50(1): 114-20.
273. Larson, E.R., Ariano, M.A. D3 and D2 dopamine receptors: Visualization of cellular expression patterns in motor and limbic structures. Synapse 1995, 20(4): 325-37.
274. Lopez-Gonzalez, M.A., Esteban-Ortega, F. Tinnitus dopaminergic pathway. Ear noises treatment by dopamine modulation. Med Hypotheses 2005, 65(2): 349-52.
275. Lopez-Gonzalez, M.A., Santiago, A.M., Esteban-Ortega, F. Sulpiride and melatonin decrease tinnitus perception modulating the auditolimbic dopaminergic pathway. J Otolaryngol 2007, 36(4): 213-9.
276. Lincoln, G.A., Tortonese, D.J. Does melatonin act on dopaminergic pathways in the mediobasal hypothalamus to mediate effects of photoperiod on prolactin secretion in the ram? Neuroendocrinology 1995, 62(5): 425-33.
277. Nguyen-Legros, J., Chanut, E., Versaux-Botteri, C., Simon, A., Trouvin, J.H. Dopamine inhibits melatonin synthesis in photoreceptor cells through a D2-like receptor subtype in the rat retina: Biochemical and histochemical evidence. J Neurochem 1996, 67(6): 2514-20.
278. Lopez-Gonzalez, M.A., Moliner-Peiro, F., Alfaro-Garcia, J, Esteban-Ortega, F. Sulpiride plus hydroxyzine decrease tinnitus perception. Auris Nasus Larynx 2007, 34(1): 23-7.
279. Seftel, A.D. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol 2004, 27(4, Suppl. 1): 114-9.
280. Ravipati, G., McClung, J.A., Aronow, W.S., Peterson, S.J., Frishman, W.H. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev 2007, 15(2): 76-86.
281. Rashid, A. The efficacy and safety of PDE5 inhibitors. Clin Cornerstone 2005, 7(1): 47-56.
282. Mazurek, B., Haupt, H., Szczepek, A.J. et al. Evaluation of vardenafil for the treatment of subjective tinnitus: A controlled pilot study. J Negat Results Biomed 2009, 8: 3.
283. Mahadevan, S., Park, Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: Chemistry, efficacy, safety, and uses. J Food Sci 2008, 73(1): R14-9.
284. Morgenstern, C., Biermann, E. The efficacy of Ginkgo special extract EGb 761 in patients with tinnitus. Int J Clin Pharmacol Ther 2002, 40(5): 188-97.
285. Jastreboff, P.J., Zhou, S., Jastreboff, M.M., Kwapisz, U., Gryczynska, U. Attenuation of salicylate-induced tinnitus by Ginkgo biloba extract in rats. Audiol Neurootol 1997, 2(4): 197-212.
286. Coles, R. Trial of an extract of Ginkgo biloba (EGB) for tinnitus and hearing loss [letter]. Clin Otolaryngol 1988, 13(6): 501-2.
287. Holgers, K.M., Axelsson, A., Pringle, I. Ginkgo biloba extract for the treatment of tinnitus. Audiology 1994, 33(2): 85-92.
288. Smith, P.F., Zheng, Y., Darlington, C.L. Ginkgo biloba extracts for tinnitus: More hype than hope? J Ethnopharmacol 2005, 100(1-2): 95-9.
289. Drew, S., Davies, E. Effectiveness of Ginkgo biloba in treating tinnitus: Double blind, placebo controlled trial. Bmj 2001, 322(7278): 73.
290. Patterson, M.B., Balough, B.J. Review of pharmacological therapy for tinnitus. Int Tinnitus J 2006, 12(2): 149-59.
291. Rejali, D., Sivakumar, A., Balaji, N. Ginkgo biloba does not benefit patients with tinnitus: A randomized placebo-controlled double-blind trial and meta-analysis of randomized trials. Clin Otolaryngol Allied Sci 2004, 29(3): 226-31.
292. Jan, J.E., Reiter, R.J., Wasdell, M.B., Bax, M. The role of the thalamus in sleep, pineal melatonin production, and circadian rhythm sleep disorders. J Pineal Res 2009, 46(1): 1-7.
293. Seggie, J., Werstiuk, E.S., Grota, L. Lithium and circadian patterns of melatonin in the retina, hypothalamus, pineal and serum. Prog Neuropsychopharmacol Biol Psychiatry 1987, 11(2-3): 325-34.
294. Berra, B., Rizzo, A.M. Melatonin: Circadian rhythm regulator, chronobiotic, antioxidant and beyond. Clin Dermatol 2009, 27(2): 202-9.
295. Jou, M.J., Peng, T.l., Yu, P.Z. et al. Melatonin protects against common deletion of mitochondrial DNA-ougmented mitochondrial oxidative stress and apoptosis. J Pineal Res 2007, 43(4): 389-403.
296. Lopez-Gonzalez, M.A., Guerrero, J.M., Rojas, F., Delgado, F. Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. J Pineal Res 2000, 28(2): 73-80.
297. Bas, E., Martinez-Soriano, F., Lainez, J.M., Marco, J. An experimental comparative study of dexamethasone, melatonin and tacrolimus in noise-induced hearing loss. Acta Otolaryngol 2009, 129(4): 385-9.
298. Rosenberg, S.I., Silverstein, H., Rowan, P.T., Olds, M.J. Effect of melatonin on tinnitus. Laryngoscope 1998, 108(3): 305-10.
299. Megwalu, U.C., Finnell, J.E., Piccirillo, J.F. The effects of melatonin on tinnitus and sleep. Otolaryngol Head Neck Surg 2006, 134(2): 210-3.
300. McFadden, S.L., Ding, D., Burkard, R.F., Jiang, H., Reaume, A.G., Flood, D.G., Salvi, R.J. Cu/Zn SOD deficiency potentiates hearing loss and cochlear pathology in aged 129,CD-1 mice. J Comp Neurol 1999, 413(1): 101-12.
301. Kaltenbach, J.A., Rachel, J.D., Mathog, T.A., Zhang, J., Falzarano, P.R., Lewandowski, M. Cisplatin-induced hyperactivity in the dorsal cochlear nucleus and its relation to outer hair cell loss: Relevance to tinnitus. J Neurophysiol 2002, 88(2): 699-714.
302. Rubio, M.E., Juiz, J.M. Chemical anatomy of excitatory endings in the dorsal cochlear nucleus of the rat: Differential synaptic distribution of aspartate aminotransferase, glutamate, and vesicular zinc. J Comp Neurol 1998, 399(3): 341-58.
303. Zirpel, L., Parks, T.N. Zinc inhibition of group I mGluR-mediated calcium homeostasis in auditory neurons. J Assoc Res Otolaryngol 2001, 2(2): 180-7.
304. Shambaugh, G.E. Jr. Zinc for tinnitus, imbalance, and hearing loss in the elderly. Am J Otol 1986, 7(6): 476-7.
305. Gersdorff, M., Robillard, T., Stein, F., Declaye, X., Van der Bernden, S. The zinc sulfate overload test in patients suffering from tinnitus associated with low serum zinc. Preliminary report. Acta Otorhinolaryngol Belg 1987, 41(3): 498-505.
306. Coelho, C.B., Tyler, R., Hansen, M. Zinc as a possible treatment for tinnitus. Prog Brain Res 2007, 166: 279-85.
307. Ochi, K., Kinoshit,a H, Kenmochi, M,, Nishino, H,, Ohashi, T. Zinc deficiency and tinnitus. Auris Nasus Larynx 2003, 30(Suppl.): S25-8.
308. Arda, H.N., Tuncel, U., Akdogan, O., Ozluoglu, L.N. The role of zinc in the treatment of tinnitus. Otol Neurotol 2003, 24(1): 86-9.
309. Paaske, P.B., Pedersen, C.B., Kjems, G., Sam, I.L. Zinc therapy of tinnitus. A placebo-controlled study. Ugeskr Laeger 1990, 152(35): 2473-5.
310. Yetiser, S., Tosun, F., Satar, B., Arslanhan, M., Akcam, T., Ozkaptan, Y. The role of zinc in management of tinnitus. Auris Nasus Larynx 2002, 29(4): 329-33.
311. Levine, R.A., Nam, E.C., Melcher, J. Somatosensory pulsatile tinnitus syndrome: somatic testing identifies a pulsatile tinnitus subtype that implicates the somatosensory system. Trends Amplif 2008, 12(3): 242-53.
312. Kirchmann, M., Thomsen, L.L., Olesen, J. Basilar-type migraine: Clinical, epidemiologic, and genetic features. Neurology 2006, 66(6): 880-6.
313. Weissman, J.L., Hirsch, B.E. Imaging of tinnitus: A review. Radiology 2000, 216(2): 342-9.
314. Branstetter, B.F.T., Weissman, J.L. The radiologic evaluation of tinnitus. Eur Radiol 2006, 16(12): 2792-802.
315. Pinchoff, R.J., Burkard, R.F., Salvi, R.J., Coad, M.L., Lockwood, A.H. Modulation of tinnitus by voluntary jaw movements. Am J Otol 1998, 19(6): 785-9.
316. Simmons, R., Dambra, C., Lobarinas, E., Stocking, C., Salvi, R. Head, neck and eye movements that modulate tinnitus. Sem Hear 2008, 29: 361-70.
317. Hanley, P.J., Davis, P.B., Paki, B., Quinn, S.A., Bellekom, S.R. Treatment of tinnitus with a customized, dynamic acoustic neural stimulus: Clinical outcomes in general private practice. Ann Otol Rhinol Laryngol 2008, 117(11): 791-9.
318. Henry, J.A., Schlechter, M.A., Zaugg, T.L. et al. Clinical trial to compare tinnitus masking and tinnitus retraining therapy. Acta Otolaryngol Suppl 2006, (556): 64-9.
319. Henry, J.A., Schechter, M.A., Zaugg, T.L. et al. Outcomes of clinical trial: Tinnitus masking versus tinnitus retraining therapy. J Am Acad Audiol 2006, 17(2): 104-32.
320. Dobie, R.A., Sullivan, M.D., Katon, W.J., Sakai, C.S., Russo, J. Antidepressant treatment of tinnitus patients. Interim report of a randomized clinical trial. Acta Otolaryngol 1992, 112(2): 242-7.
321. Paul, A.K., Lobarinas, E., Simmons, R. et al. Metabolic imaging of rat brain during pharmacologically-induced tinnitus. Neuroimage 2009, 44(2): 312-8.